Annual Total Long Term Liabilities
$304.67 M
+$45.09 M+17.37%
December 31, 2023
Summary
- As of February 7, 2025, AVBP annual total long term liabilities is $304.67 million, with the most recent change of +$45.09 million (+17.37%) on December 31, 2023.
- During the last 3 years, AVBP annual total long term liabilities has risen by +$304.67 million (+100.00%).
- AVBP annual total long term liabilities is now at all-time high.
Performance
AVBP Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$304.67 M
+$304.57 M+310784.69%
September 1, 2024
Summary
- As of February 7, 2025, AVBP quarterly total long term liabilities is $304.67 million, with the most recent change of +$304.57 million (+310784.69%) on September 1, 2024.
- Over the past year, AVBP quarterly long term liabilities has increased by +$304.57 million (+310784.69%).
- AVBP quarterly long term liabilities is now at all-time high.
Performance
AVBP Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
AVBP Long Term Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +17.4% | +10000.0% |
| 3 y3 years | +100.0% | +10000.0% |
| 5 y5 years | +100.0% | +10000.0% |
AVBP Long Term Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | -100.0% | at high | -100.0% |
| 5 y | 5-year | at high | -100.0% | at high | -100.0% |
| alltime | all time | at high | -100.0% | at high | -100.0% |
ArriVent BioPharma Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $304.67 M(>+9900.0%) |
| Jun 2024 | - | $98.00 K(-29.0%) |
| Mar 2024 | - | $138.00 K(-100.0%) |
| Dec 2023 | $304.67 M | $304.67 M(+0.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2023 | - | $304.49 M(>+9900.0%) |
| Jun 2023 | - | $0.00(-100.0%) |
| Dec 2022 | $259.58 M(>+9900.0%) | - |
| Dec 2022 | - | $259.58 M |
| Dec 2021 | $0.00 | - |
FAQ
- What is ArriVent BioPharma annual total long term liabilities?
- What is the all time high annual total long term liabilities for ArriVent BioPharma?
- What is ArriVent BioPharma annual total long term liabilities year-on-year change?
- What is ArriVent BioPharma quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for ArriVent BioPharma?
- What is ArriVent BioPharma quarterly long term liabilities year-on-year change?
What is ArriVent BioPharma annual total long term liabilities?
The current annual total long term liabilities of AVBP is $304.67 M
What is the all time high annual total long term liabilities for ArriVent BioPharma?
ArriVent BioPharma all-time high annual total long term liabilities is $304.67 M
What is ArriVent BioPharma annual total long term liabilities year-on-year change?
Over the past year, AVBP annual total long term liabilities has changed by +$45.09 M (+17.37%)
What is ArriVent BioPharma quarterly total long term liabilities?
The current quarterly long term liabilities of AVBP is $304.67 M
What is the all time high quarterly long term liabilities for ArriVent BioPharma?
ArriVent BioPharma all-time high quarterly total long term liabilities is $304.67 M
What is ArriVent BioPharma quarterly long term liabilities year-on-year change?
Over the past year, AVBP quarterly total long term liabilities has changed by +$304.57 M (+310784.69%)